FDA Inspection 1265843 — Rigel Pharmaceuticals Inc
The FDA completed an inspection of Rigel Pharmaceuticals Inc on March 28, 2025 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 28, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- South San Francisco, CA (United States)